{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir%2Femtricitabine%2Fefavirenz&page=3", "query": { "intervention": "Tenofovir/emtricitabine/efavirenz", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 57, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir%2Femtricitabine%2Fefavirenz&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir%2Femtricitabine%2Fefavirenz&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T04:48:30.337Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01815736", "title": "Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "EFV/FTC/TDF", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1443, "start_date": "2013-03-27", "completion_date": "2020-04-01", "has_results": true, "last_update_posted_date": "2021-04-13", "last_synced_at": "2026-10-10T04:48:30.337Z", "location_count": 91, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01815736" }, { "nct_id": "NCT02121795", "title": "Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "FTC/TDF", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "Allowed third antiretroviral agent", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 668, "start_date": "2014-05-06", "completion_date": "2019-03-01", "has_results": true, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-10-10T04:48:30.337Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02121795" }, { "nct_id": "NCT00862823", "title": "The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "tenofovir, emtricitabine and efavirenz fixed dose tablet", "type": "DRUG" }, { "name": "tenofovir, emtricitabine and efavirenz tablet added to solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "19 Years to 65 Years" }, "enrollment_count": 14, "start_date": "2009-02", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2012-09-14", "last_synced_at": "2026-10-10T04:48:30.337Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00862823" }, { "nct_id": "NCT00118898", "title": "Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Abacavir/Lamivudine", "type": "DRUG" }, { "name": "Atazanavir", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Emtricitabine/Tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Abacavir/Lamivudine placebo", "type": "DRUG" }, { "name": "Emtricitabine/Tenofovir disoproxil fumarate placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 1864, "start_date": "2005-09", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2018-10-12", "last_synced_at": "2026-10-10T04:48:30.337Z", "location_count": 51, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 30 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118898" }, { "nct_id": "NCT00988780", "title": "Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Immune Reconstitution Inflammatory Syndrome", "HIV", "HIV Infections" ], "interventions": [ { "name": "maraviroc", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 276, "start_date": "2009-12", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2012-11-27", "last_synced_at": "2026-10-10T04:48:30.337Z", "location_count": 4, "location_summary": "Bethesda, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00988780" }, { "nct_id": "NCT02285114", "title": "Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1" ], "interventions": [ { "name": "F/TAF", "type": "DRUG" }, { "name": "3rd ARV agent", "type": "DRUG" }, { "name": "Boosted PIs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Month to 17 Years" }, "enrollment_count": 41, "start_date": "2015-01-20", "completion_date": "2024-12-11", "has_results": true, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-10-10T04:48:30.337Z", "location_count": 4, "location_summary": "Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02285114" }, { "nct_id": "NCT01180075", "title": "Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)", "type": "DRUG" }, { "name": "tenofovir/emtricitabine (TDF/FTC)", "type": "DRUG" }, { "name": "Atazanavir (ATV)", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Phlebotomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2010-05", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2014-12-02", "last_synced_at": "2026-10-10T04:48:30.337Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01180075" }, { "nct_id": "NCT01293123", "title": "Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Raltegravir", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2, "start_date": "2011-12", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2019-10-31", "last_synced_at": "2026-10-10T04:48:30.337Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01293123" }, { "nct_id": "NCT01338883", "title": "Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Cenicriviroc 100 mg", "type": "DRUG" }, { "name": "Cenicriviroc 200 mg + Truvada", "type": "DRUG" }, { "name": "Sustiva + Truvada", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tobira Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2011-06", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-10-10T04:48:30.337Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01338883" }, { "nct_id": "NCT01309243", "title": "Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "FTC/RPV/TDF", "type": "DRUG" }, { "name": "EFV/FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 799, "start_date": "2011-02", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2015-02-25", "last_synced_at": "2026-10-10T04:48:30.337Z", "location_count": 83, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01309243" } ] }